Prospective, Observational Study of the Clinical Outcomes of FVIII Treatment in Adults and Adolescents with Severe Haemophilia A
TH Open · 17.06.2025 · 09 (CP)
DOI: 10.1055/a-2621-9749 ↗Kurz gefasst
Fachartikel in der Zeitschrift TH Open, erschienen am 17.06.2025. Verfasst von Pratima Chowdary und 6 weiteren Autor:innen. Beteiligte Einrichtung: Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi and Sobi.
Abstract (Originalsprache)
To assess real-world treatment patterns and outcomes in previously treated patients ≥12 years old with severe haemophilia A treated with marketed factor VIII (FVIII) replacement products. Data were collected prospectively between 25 January 2019 and 30 November 2020 across 45 sites in 17 countries. Primary endpoint was annualized bleed rate (ABR). Secondary endpoints included factor consumption, bleed treatment, joint health, and safety. Exploratory endpoints included pain and quality of life outcomes. A total of 157 patients received ≥1 FVIII injection (prophylaxis n = 139, on-demand n = 19). Mean (standard deviation; SD) observation period was 43.1 (13.3) weeks. Median (quarter [Q]1, Q3) ABR was 2.0 (0.0, 5.7) for those on prophylaxis. Those receiving standard half-life FVIII products or extended half-life FVIII products had a median (IQR) ABR of 2.2 (0.0, 6.1) and 1.3 (0.0, 5.0), respectively. Still, only 35% of patients on prophylaxis experienced zero bleeds and 18% had more than five bleeds in a year. Approximately 23% of bleeding episodes required >1 FVIII dose for resolution. The mean (SD) number of routine prophylaxis injections/week was 2.2 (1.1). Median (Q1, Q3) annualized factor consumption for patients on prophylaxis was 4,106.4 (3,151.6, 5,291.2) IU/kg/year. No changes in Haemophilia Joint Health Score (mean [SD] of 16.1 [19.3] versus 15.7 [17.7]), PROMIS pain intensity 3a T-score (mean [SD] 41.6 [8.2] versus 40.9 [9.1]), or Haem-A-QoL (mean [SD] 30.6 [17.3] versus 29.5 [17.4]) were observed between baseline and the end of the observation period for those using prophylaxis. Prophylaxis using standard or extended half-life FVIII replacement therapies achieves adequate haemostatic control in only about half of patients, with some experiencing very poor outcomes. Real-world data highlight the urgent need to optimize prophylaxis to enhance haemostatic control, ideally achieving a zero ABR and its associated benefits.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom.
- Department of Haematology, Cancer Institute, University College London, London, United Kingdom.
- Haemophilia Treatment Centre, Royal Prince Alfred Hospital, Sydney, Australia.
- Hemophilia and Thrombosis Center, University of Colorado Anschutz Medical Campus, Colorado, United States.
- AP-HM, Department of Pediatric Hematology Oncology, Children Hospital La Timone & Aix Marseille University, INSERM, INRA, C2VN, Marseille, France.
- Department of Pediatrics, McMaster Children's Hospital, McMaster University, Ontario, Canada.
Förderung
- Sanofi and Sobi
Zitieren
APA
Chowdary, P., Khoo, L., Wang, M., Chambost, H., Chan, A. K. C., Willemze, A., & Oldenburg, J. (2025). Prospective, Observational Study of the Clinical Outcomes of FVIII Treatment in Adults and Adolescents with Severe Haemophilia A. TH Open, 09(CP). https://doi.org/10.1055/a-2621-9749
Vancouver
Chowdary P, Khoo L, Wang M, Chambost H, Chan AKC, Willemze A, et al. Prospective, Observational Study of the Clinical Outcomes of FVIII Treatment in Adults and Adolescents with Severe Haemophilia A. TH Open. 2025;09(CP). doi:10.1055/a-2621-9749
BibTeX
@article{Chowdary2025,
author = {Chowdary, Pratima and Khoo, Liane and Wang, Michael and Chambost, Hervé and Chan, Anthony K C and Willemze, Annemieke and Oldenburg, Johannes},
title = {Prospective, Observational Study of the Clinical Outcomes of FVIII Treatment in Adults and Adolescents with Severe Haemophilia A},
journal = {TH Open},
year = {2025},
volume = {09},
number = {CP},
doi = {10.1055/a-2621-9749}
}
EUVIMED